The drug exhibited greater treatment persistence and control of moderate-to-severe PsO symptoms compared to secukinumab and ixekizumab
Cipla has recently signed an agreement to make and market the diabetes therapy Galvus and its combination brands in India from 01 January 2026.
Abbas will closely partner with CBC's business teams to identify, assess, and pursue investment opportunities and strategic acquisitions
Julie is recognized as a highly engaging multi-cultural leader skilled in fluidly partnering with cross-functional teams to deliver results.
The Innovation Explorer database of GlobalData’s Disruptor Intelligence Center highlights the key company collaborations in pharma to advance AI-powered drug repurposing techniques.
The supplemental New Drug Application is based on results from the landmark EMPA-KIDNEY phase III trial
To create leading company developing medicines targeting metalloenzymes
Allam was serving recently as the CEO at Public Investment Fund
Phase III trial also demonstrated a statistically significant reduction (14%) in hospitalization for any cause, bringing potential relief for patients and reducing burden on healthcare systems
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
